Table 1

Studies included in the NMA

StudyTreatment armsNo. patients (N)Timepoint (weeks)Outcomes included in NMA
ASTRAEA24Placebo21116ACR–20, 50, 70; PASI 75*; EnthR*; DactR*; DAE
Abatacept 125 mg213
ADEPT70Placebo16212ACR–20, 50, 70; PASI–75, 90; DAE
Adalimumab 40 mg153
Genovese 200771Placebo5112ACR–20, 50, 70; DAE
Adalimumab 40 mg51
Mease 201861Placebo2412ACR–20, 50, 70; PASI–75; 90; DAE
Adalimumab 40 mg72
Remtolumab 120 mg71
Remtolumab 240 mg73
ACTIVE62Placebo10916ACR–20, 50, 70; DAE
Apremilast 30 mg twice daily110
Schett 201236Placebo6812ACR–20, 50, 70; DAE
Apremilast 20 mg twice daily69
Apremilast 40 mg once daily67
PALACE 137Placebo16816ACR–20, 50, 70; PASI 75*; EnthR; DactR; DAE
Apremilast 20 mg twice daily168
Apremilast 30 mg twice daily168
PALACE 238Placebo15916ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE
Apremilast 20 mg twice daily163
Apremilast 30 mg twice daily162
PALACE 339Placebo16916ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE
Apremilast 20 mg twice daily169
Apremilast 30 mg twice daily167
Mease 201422Placebo5512ACR–20, 50, 70; DAE
Brodalumab 140 mg57
Brodalumab 280 mg56
AMVISION 123Placebo16116ACR–20, 50, 70; PASI–75, 90;
EnthR; DactR; DAE
Brodalumab 140 mg158
Brodalumab 210 mg159
AMVISION 223Placebo16116ACR–20, 50, 70; PASI–75, 90;
EnthR; DactR; DAE
Brodalumab 140 mg160
Brodalumab 210 mg163
RAPID-PsA40Placebo13612ACR–20, 50, 70; PASI–75, 90; DAE
Certolizumab 200 mg every two weeks138
Certolizumab 400 mg every four weeks135
Mease 200472Placebo10412ACR–20, 50, 70; PASI 75*; DAE
Etanercept 25 mg twice weekly101
PRESTA63Etanercept 50 mg once weekly37312ACR–20, 50, 70; PASI 75*; DAE
Etanercept 50 mg twice weekly379
SEAM-PsA66Placebo +MTX 20 mg once weekly28416ACR–20, 50, 70; DAE
Placebo +Etanercept 50 mg once weekly284
Etanercept 50 mg +MTX 20 mg once weekly283
EQUATOR26Placebo6616ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE
Filgotinib 200 mg65
GO-REVEAL41Placebo11314ACR–20, 50, 70; PASI–75, 90; DAE
Golimumab 50 mg146
Golimumab 100 mg146
GO-VIBRANT42Placebo23914ACR–20, 50, 70; PASI–75, 90; DAE
Golimumab 2 mg/kg241
GO-DACT64Placebo +MTX 15–25 mg2312DactR
Golimumab 50 mg +MTX 15–25 mg21
DISCOVER 117Placebo12616ACR–20, 50, 70; PASI*–75, 90; EnthR*, DactR*; DAE
Guselkumab 100 mg every eight weeks128
Guselkumab 100 mg every four weeks128
DISCOVER 218Placebo24716ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE
Guselkumab 100 mg every eight weeks248
Guselkumab 100 mg every four weeks246
Deodhar 201819Placebo4916ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE
Guselkumab 100 mg every eight weeks100
IMPACT43Placebo5216ACR–20, 50, 70; PASI–75, 90; DAE
Infliximab 5 mg/kg52
IMPACT 244Placebo10014ACR–20, 50, 70; PASI–75, 90; DAE
Infliximab 5 mg/kg100
RESPOND65Infliximab 5 mg/kg+MTX 15 mg5716ACR–20, 50, 70; PASI–75, 90; DAE
MTX 15 mg58
SPIRIT H2H45Adalimumab 40 mg28316ACR–50; PASI*–75, 90; EnthR*; DactR*; DAE
Ixekizumab 80 mg283
SPIRIT P146Placebo10612ACR–20, 50, 70; PASI–75, 90; EnthR†; DactR†; DAE
Adalimumab 40 mg101
Ixekizumab 80 mg every four weeks107
Ixekizumab 80 mg every two weeks103
SPIRIT P247Placebo11812ACR†–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE
Ixekizumab 80 mg every four weeks122
Ixekizumab 80 mg every two weeks123
PATERA48Placebo9724ACR–20, 50, 70
Netakimab 120 mg97
CHOICE49Placebo5216ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE
Secukinumab 150 mg103
Secukinumab 300 mg103
FUTURE 150Placebo20216ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE
Secukinumab 75 mg (IV LD)202
Secukinumab 150 mg (IV LD)202
FUTURE 251Placebo9816ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE
Secukinumab 75 mg (SC LD)99
Secukinumab 150 mg100
Secukinumab 300 mg100
FUTURE 367Placebo13716ACR–20, 50; PASI*–75, 90; EnthR*; DactR*; DAE
Secukinumab 150 mg138
Secukinumab 300 mg139
FUTURE 468Placebo11416ACR–20, 50, 70; PASI–75, 90; EnthR; DactR
Secukinumab 150 mg (no LD)113
Secukinumab 150 mg114
FUTURE 552Placebo33216ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE
Secukinumab 150 mg (no LD)222
Secukinumab 150 mg220
Secukinumab 300 mg222
EXCEED53Adalimumab 40 mg42716ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE
Secukinumab 300 mg426
MAXIMISE69Placebo16612ACR 20
Secukinumab 150 mg165
Secukinumab 300 mg167
Gottlieb 201920Placebo7916ACR–20, 50, 70; PASI–75, 90; DAE
Tildrakizumab 20 mg78
Tildrakizumab 100 mg77
Tildrakizumab 200 mg79
Opal Beyond54Placebo13113ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE
Tofacitinib 5 mg twice daily131
Tofacitinib 10 mg twice daily132
Opal Broaden55Placebo10513ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE
Adalimumab 40 mg106
Tofacitinib 5 mg twice daily107
Tofacitinib 10 mg twice daily104
SELECT-PsA 156Placebo42316ACR‡–20, 50, 70; PASI 75; EnthR1; DactR1; DAE
Upadacitinib 15 mg once daily429
Upadacitinib 30 mg once daily423
Adalimumab 40 mg429
SELECT-PsA 257Placebo21216ACR‡–20, 50, 70; PASI 75; EnthR; DactR; DAE
Upadacitinib 15 mg once daily211
Upadacitinib 30 mg once daily218
Gottlieb 200958Placebo7012ACR–20, 50, 70; PASI–75, 90; DAE
Ustekinumab 90 mg76
PSUMMIT 159Placebo20616ACR–20; PASI 75*; EnthR*; DactR*; DAE
Ustekinumab 45 mg205
Ustekinumab 90 mg204
PSUMMIT 260Placebo10416ACR–20; PASI 75*; EnthR*; DactR*; DAE
Ustekinumab 45 mg103
Ustekinumab 90 mg105

  • *Data reported at week 24.

  • †Data reported at week 16.

  • ‡Data reported at week 12.

  • ACR, American College of Rheumatology; DactR, resolution of dactylitis; DAE, withdrawal due to adverse events; EnthR, resolution of enthesitis; IV, intravenous; LD, loading dose; MTX, methotrexate; NMA, network meta-analysis; PASI, Psoriasis Area and Severity Index; SC, subcutaneous.